Dalutrafusp alfa

N/A

Report date: 2024/04/12 13:56:18

Base Information

Drug NameDalutrafusp alfa
Drug Alias NameGS-1423AGEN-1423
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of Action5'-nucleotidase inhibitorsTransforming growth factor beta 1 inhibitorsTransforming growth factor beta 3 inhibitors
Targets5'-nucleotidaseTransforming growth factor beta 1Transforming growth factor beta 3
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsLiver Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAgenus Inc
China Registration ClassN/A

Develop Information

Active CompaniesAgenus Inc
Inactive CompaniesGilead Sciences Inc
Active IndicationsPancreatic NeoplasmsLiver NeoplasmsColorectal Neoplasms +[4] 
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A